Saturday, November 27, 2021 9:59:13 PM
Yep. I sold in August before the crash. It got to the point where the risk was greater than the reward. When the NIH changed the primary endpoint of the ACTIV-5, that was a sign that the EUA was not coming in the short term.
But the gamble is different now. HGEN might fall to $4 with a UK rejection. Then it will rebound to $5 or $6 because of CAR-T. Long term, HGEN is worth more than $6 per share just from CAR-T alone. It is probably worth $60 per share from CAR-T alone. But the Covid investors skew it in the short term.
HGEN will still look promising for a US FDA EUA after a UK rejection. Lenz is still the most efficacious Covid therapeutic according to the data. Maybe the UK will authorize, but it is still a good investment if they reject. I was worried in August so I sold. I am no longer worried now at $6.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM